Sexual Libido Performance Enhancing Peptides PT-141 Bremelanotide 10mg

PT-141 (Bremelanotide) is the first of a new class of drugs called melanocortin agonists being developed to treat sexual dysfunction.The mechanism of action of PT-141 (Bremelanotide) may offer significant safety and efficacy benefits over currently available products because it acts on the pathway that controls sexual function without acting directly on the vascular system.Clinical data indicates that PT-141 (Bremelanotide) may be effective in treating a broad range of patients suffering from ED.

The nasal formulation of PT-141 (Bremelanotide) being developed is as convenient as oral treatments, is more patient-friendly than invasive treatments for ED, such as injections and trans-urethral pellets, and appears to result in a rapid onset of action.Bremelanotide (PT-141) was developed from Melanotan 2 (MT-II).PT-141 is a metabolite of MT-II that lacks the C-terminal amide function-stripping away tanning properties.

PT-141 or Bremelanotide is the generic term for a research peptide being studied for its possible use in helping to improve sexual dysfunction in both men and women. PT-141 was developed from the tanning peptide Melanotan 2, which is a synthetically produced variant of a peptide hormone naturally produced in the body that stimulates melanogenesis that is known as alpha-Melanocyte stimulating hormone. MSH, activates certain melanocortin receptors in the process of exerting its effects. Indeed, MSH also exerts potent influence over lipid metabolism, appetite, and sexual libido.

PT-141 is a synthetic amino acid protein discovered during clinical trials using the Melanotan 2 for sunless tanning, photo-protection results from melanotans. The melanocortin system targets receptors associated with desire through the melanocyte stimulating hormone paths that cross the blood-brain-barrier. Potentially the powerful sex-drug results feeling an aphrodisiac experience amplifying arousal pt141 reviews have shown the ability to increase libido effects of both men and women

PT-141(Bremelanotide)is the first of a new class of drugs called melanocortin agonists being developed to treat sexual dysfunction. The mechanism of action of PT-141 (Bremelanotide)may offer significant safety and efficacy benefits over currently available products because it acts on the pathway that controls sexual function without acting directly on the vascular system. PT-141 comes in 10mg vials. As a lifestyle peptide, the 10mg product is a lot to consume and may offer up to 20 doses when dosing light. The PT-141 peptide reconstituted with bacteriostatic water remains potent in the fridge for months.

PT-141 is a potential remedy for the treatment of sexual dysfunction; specifically, male erectile dysfunction. Studies have shown that PT-141 does not act on the vascular system like former compounds, but allegedly works by activating melanocortin receptors in the brain, therefore helping increase ones sexual stimulation. PT-141 is a melanocortin based peptide that has shown effectiveness in clinical studies on both male and female rats. Male rats have shown erectile response with doses as low as 1-2 mgs whereas most female rats have shown positive results with higher doses around 2-3 mgs.

Used as an erectile dysfunction solution, it is used by men who want to bring back the fire into their sex life in terms of achieving rock-hard erections that do not only satisfy them but their partners as well. In the process, they never have to take any other medications or choose hormone replacement therapy again with it at their side.


Potential benefits

PT-141 in Men:

• effective in a broad range of patients, including those with severe ED and those non-responsive to sildenafil
• efficacy in "at-home" studies is comparable to PDE-5 inhibitors
• up to 50% of ED patients were restored to a normal level of function
• co-administration with sildenafil shows superior efficacy
• side effects include facial flushing, nausea, aftertaste and post-nasal drip

PT-141 in Women:

Palatin conducted a Phase 2A study in 18 premenopausal women with a diagnosis of female sexual
dysfunction (FSD). Patients reported a significant increase in sexual desire and in genital arousal after
receiving PT-141, compared to
placebo. Additionally, there was a correlation between sexual desire and genital arousal in patients receiving
PT-141, an observation that further reinforces the potential importance of these reports.